Sequent Scientific completes merger, names new MD and CFO

Sequent Scientific Limited announced its composite scheme of amalgamation became effective on December 16, 2025. This led to the allotment of 1,819,21,827 equity shares of Sequent to shareholders of Viyash, as per a 56:100 share exchange ratio. Concurrently, the company approved the allotment of 2,03,41,257 share warrants at an issue price of INR 181.94 per warrant, with an upfront payment of INR 92,52,22,075 received. These changes will increase Sequent’s paid-up equity share capital from INR 50,82,25,298 to INR 87,20,68,952.

The board also approved significant management changes, including the appointment of Dr. Haribabu Bodepudi as managing director and group CEO, Mr. Srinivas Vasireddy as an additional director, and Mr. Ramakant Singani as chief financial officer and KMP, all effective December 16, 2025 (except for Mr. Singani, effective January 1, 2026). Mr. Rajaram Narayanan's designation changed to whole-time director and CEO – animal health, effective December 16, 2025. Mr. Saurav Bhala resigned as CFO, effective January 1, 2026.

CA Hull Investments became a promoter of Sequent, and Appco Pharma LLC became a material subsidiary. The company's authorized share capital was revised to INR 8,86,14,70,000.